Anubhav Gupta1, Sanjeet Kumar Pandit2, Anand Dev3, B. Kumar4, Vishva Nayak5, Ankit Gupta6
AIMS AND OBJECTIVES
To Compare the Safety and Efficacy of Rosuvastatin (10 Mg) and Atorvastatin (20 Mg) in Cases of Dyslipidaemia Over Six Weeks of Treatment.
MATERIALS AND METHODS
Inclusion Criteria: Both male and female (Excluding Pregnancy) above 18 years of age with hypercholesterolaemia, having LDL-C concentration of >159 and, 259 mg/dL and triglyceride concentration of <400 mg/dL, who had failed to have achieved LDL-C goals laid down by the NECP ATP-III guidelines after therapeutic lifestyle change (TLC): HDL-C level: <40 mg/dL for men and, <50 mg/dL for women. 60 cases of dyslipidaemia were selected and 30 were treated with rosuvastatin 10 mg (Study group ‘A’) and 30 of them were treated with atorvastatin 20 mg (study group ‘B’).
1. Use of lipid lowering agents within the past 6 months.
2. Any history of known familial hypercholesterolaemia.
3. Any history of serious or hypersensitivity reactions to other statins.
4. Uncontrolled hypothyroidism; uncontrolled hypertension.
5. Acute liver diseases or hepatic dysfunction.
After estimation of total cholesterol, triglycerides, HDL- cholesterol and LDL-c in a basal state, 30 patients were put on rosuvastatin 10 mg and 30 patients were put on atorvastatin 20 mg daily after night meals. After taking drugs, lipid fractions were re-estimated at the end of 4 weeks and 6 weeks. Clinical examination and questions about occurrence of side effects were carried out at interval of 2 weeks. Present study was conducted in the Department of Medicine and Pathology, of Katihar Medical College, Katihar, B. N. Mandal University, Madhepura; Bihar. Approval of the Institutional Ethical Committee was taken.
Study conducted by “Keith C et al (2006)” showed 37.1±1.3%, improvement in patients treated with RSV (10) and 38.5±1%, with (ATV 20), (ARIES TRIAL), “Cheng J. W. et al (2004)” found 43% improvement in levels of LDL-C, with RSV (10) and “Herregod et al (2008)” found that RSV (10) significantly reduced LDL level up to 47% in his study. In the “SOLAR TRIAL” conducted by “Insull W Jr. et al (2007)1”, it was found that mean levels of LDL-C in patients taking RSV(10) over six weeks reached their target <100 mg/dL, which were comparable 100.43±2.93 to our study. The most frequent adverse effect in both the groups were myalgia with incidence of 3.33% in study. Group’ A’ (RSV 10 mg) and 6.66% incidence in study Group ‘B’ (ATV 20 mg), all adverse events were mild and had no action taken, and resolved spontaneously.
SUMMARY AND CONCLUSION
The present study “Comparison of Safety and Efficacy of Rosuvastatin (10 mg) and Atorvastatin (20 mg) in cases of Dyslipidaemia over six-week Treatment” was conducted amongst 60 diagnosed patients of dyslipidaemia. The result of this study shows that rosuvastatin 10 mg is more efficacious and safe in reducing the levels of TC, LDL, TC/HDL, TG and improving HDL levels as compared to Atorvastatin 20 mg.